1. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study
- Author
-
Luca Arecco, Maria Maddalena Latocca, Eva Blondeaux, Ferdinando Riccardi, Carmela Mocerino, Valentina Guarneri, Eleonora Mioranza, Giancarlo Bisagni, Elisa Gasparini, Fabio Puglisi, Alexandro Membrino, Antonella Ferro, Vincenzo Adamo, Filippo Giovanardi, Stefano Tamberi, Sara Donati, Elisabetta Landucci, Laura Biganzoli, Sara Piccinini, Simona Pastorino, Evandro de Azambuja, Francesca Poggio, Matteo Lambertini, and Lucia Del Mastro
- Subjects
Breast cancer ,Premenopausal patients ,Adjuvant endocrine therapy ,Tamoxifen ,Aromatase inhibitors ,Ovarian function suppression ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background: Most premenopausal patients with early breast cancer (eBC) are diagnosed with hormone receptor-positive disease and therefore candidate for adjuvant endocrine therapy (ET). Patients and methods: The Gruppo Italiano Mammella (GIM) 23-POSTER (GIM23) is a multicenter, prospective, observational study conducted in 26 Italian institutions, aiming to evaluate ET choices for premenopausal patients affected by hormone receptor-positive eBC in a real-world setting. Here we report also the results in terms of type of ET prescribed according to the definition of high-risk patients by monarchE and NATALEE trials. Results: Between October 2019 and June 2022, 600 premenopausal patients were included, with a median age of 46 years. Almost half (271, 45.2 %) of the patients had stage I disease, while 254 (42.3 %) and 60 (10.0 %) patients had stage II and III, respectively. Overall, 149 (25.1 %) patients received tamoxifen alone, 83 (14.0 %) tamoxifen with ovarian function suppression (OFS), while 361 (60.9 %) received aromatase inhibitor (AI) with OFS. Patients treated with AI and OFS had higher number of metastatic axillary nodes, higher grade and more often received chemotherapy (all p
- Published
- 2024
- Full Text
- View/download PDF